Cargando…

Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial

BACKGROUND: The initial therapy for a stenosis in an arteriovenous fistula used for haemodialysis is radiological balloon dilatation or angioplasty. The benefit of angioplasty is often short-lived, intervention-free survival is reported to be 40–50 % at 1 year. Previous small studies and observation...

Descripción completa

Detalles Bibliográficos
Autores principales: Karunanithy, Narayan, Mesa, Irene Rebollo, Dorling, Anthony, Calder, Francis, Katsanos, Konstantinos, Semik, Vikki, Robinson, Emily, Peacock, Janet, Das, Neelanjan, Forman, Colin, Lawman, Sarah, Steiner, Kate, Wilkins, C Jason, Robson, Michael G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866413/
https://www.ncbi.nlm.nih.gov/pubmed/27175481
http://dx.doi.org/10.1186/s13063-016-1372-7
_version_ 1782431916174082048
author Karunanithy, Narayan
Mesa, Irene Rebollo
Dorling, Anthony
Calder, Francis
Katsanos, Konstantinos
Semik, Vikki
Robinson, Emily
Peacock, Janet
Das, Neelanjan
Forman, Colin
Lawman, Sarah
Steiner, Kate
Wilkins, C Jason
Robson, Michael G
author_facet Karunanithy, Narayan
Mesa, Irene Rebollo
Dorling, Anthony
Calder, Francis
Katsanos, Konstantinos
Semik, Vikki
Robinson, Emily
Peacock, Janet
Das, Neelanjan
Forman, Colin
Lawman, Sarah
Steiner, Kate
Wilkins, C Jason
Robson, Michael G
author_sort Karunanithy, Narayan
collection PubMed
description BACKGROUND: The initial therapy for a stenosis in an arteriovenous fistula used for haemodialysis is radiological balloon dilatation or angioplasty. The benefit of angioplasty is often short-lived, intervention-free survival is reported to be 40–50 % at 1 year. Previous small studies and observational data suggest that paclitaxel-coated balloons may be of benefit in improving outcomes after fistuloplasty of stenotic arteriovenous fistulae. METHODS/DESIGN: We have designed a multicentre, double-blind randomised controlled trial to test the superiority of paclitaxel-coated balloons for preventing restenosis after fistuloplasty in patients with a native arteriovenous fistula. Two hundred and eleven patients will be followed up for a minimum of 1 year. Inclusion criteria include a clinical indication for a fistuloplasty, an access circuit that is free of synthetic graft material or stents, and a residual stenosis of 30 % or less after plain balloon fistuloplasty. Exclusion criteria include a synchronous venous lesion in the same access circuit, location of the stenosis central to the thoracic inlet or a thrombosed access circuit at the time of treatment. The primary endpoint is time to end of target lesion primary patency. This is defined as a clinically-driven radiological or surgical re-intervention at the treatment segment, thrombosis that includes the treatment segment, or abandonment of the access circuit due to an inability to re-treat the treatment segment. Secondary endpoints include angiographic late lumen loss, time to end of access circuit cumulative patency, the total number of interventions, and quality of life. The trial is funded by the National Institute for Health Research. DISCUSSION: We anticipate that this trial will provide rigorous data that will determine the efficacy of additional paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis. TRIAL REGISTRATION: ISRCTN14284759. Registered on 28 October 2015.
format Online
Article
Text
id pubmed-4866413
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48664132016-05-14 Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial Karunanithy, Narayan Mesa, Irene Rebollo Dorling, Anthony Calder, Francis Katsanos, Konstantinos Semik, Vikki Robinson, Emily Peacock, Janet Das, Neelanjan Forman, Colin Lawman, Sarah Steiner, Kate Wilkins, C Jason Robson, Michael G Trials Study Protocol BACKGROUND: The initial therapy for a stenosis in an arteriovenous fistula used for haemodialysis is radiological balloon dilatation or angioplasty. The benefit of angioplasty is often short-lived, intervention-free survival is reported to be 40–50 % at 1 year. Previous small studies and observational data suggest that paclitaxel-coated balloons may be of benefit in improving outcomes after fistuloplasty of stenotic arteriovenous fistulae. METHODS/DESIGN: We have designed a multicentre, double-blind randomised controlled trial to test the superiority of paclitaxel-coated balloons for preventing restenosis after fistuloplasty in patients with a native arteriovenous fistula. Two hundred and eleven patients will be followed up for a minimum of 1 year. Inclusion criteria include a clinical indication for a fistuloplasty, an access circuit that is free of synthetic graft material or stents, and a residual stenosis of 30 % or less after plain balloon fistuloplasty. Exclusion criteria include a synchronous venous lesion in the same access circuit, location of the stenosis central to the thoracic inlet or a thrombosed access circuit at the time of treatment. The primary endpoint is time to end of target lesion primary patency. This is defined as a clinically-driven radiological or surgical re-intervention at the treatment segment, thrombosis that includes the treatment segment, or abandonment of the access circuit due to an inability to re-treat the treatment segment. Secondary endpoints include angiographic late lumen loss, time to end of access circuit cumulative patency, the total number of interventions, and quality of life. The trial is funded by the National Institute for Health Research. DISCUSSION: We anticipate that this trial will provide rigorous data that will determine the efficacy of additional paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis. TRIAL REGISTRATION: ISRCTN14284759. Registered on 28 October 2015. BioMed Central 2016-05-12 /pmc/articles/PMC4866413/ /pubmed/27175481 http://dx.doi.org/10.1186/s13063-016-1372-7 Text en © Karunanithy et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Karunanithy, Narayan
Mesa, Irene Rebollo
Dorling, Anthony
Calder, Francis
Katsanos, Konstantinos
Semik, Vikki
Robinson, Emily
Peacock, Janet
Das, Neelanjan
Forman, Colin
Lawman, Sarah
Steiner, Kate
Wilkins, C Jason
Robson, Michael G
Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial
title Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial
title_full Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial
title_fullStr Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial
title_full_unstemmed Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial
title_short Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial
title_sort paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (pave): study protocol for a randomised controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866413/
https://www.ncbi.nlm.nih.gov/pubmed/27175481
http://dx.doi.org/10.1186/s13063-016-1372-7
work_keys_str_mv AT karunanithynarayan paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT mesairenerebollo paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT dorlinganthony paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT calderfrancis paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT katsanoskonstantinos paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT semikvikki paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT robinsonemily paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT peacockjanet paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT dasneelanjan paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT formancolin paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT lawmansarah paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT steinerkate paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT wilkinscjason paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial
AT robsonmichaelg paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial